Search company, investor...

Halozyme Therapeutics

Total Raised

$20.27M

Investors Count

6

Funding, Valuation & Revenue

4 Fundings

Halozyme Therapeutics has raised $20.27M over 4 rounds.

Halozyme Therapeutics's latest funding round was a IPO for on May 10, 2007.

Date	Round	Amount	Investors	Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.	Revenue	Sources
5/10/2007	IPO		Public	$99M	0 FY undefined	2
12/5/2006	Unattributed VC - II	$99M	Subscribe to see more	$99M	0 FY undefined	0
2/23/2004	Unattributed VC	$99M	Subscribe to see more	$99M	0 FY undefined	0
	Other Investors		Subscribe to see more	$99M	0 FY undefined	0

Date	5/10/2007	12/5/2006	2/23/2004
Round	IPO	Unattributed VC - II	Unattributed VC	Other Investors
Amount		$99M	$99M
Investors	Public	Subscribe to see more	Subscribe to see more	Subscribe to see more
Valuation	$99M	$99M	$99M	$99M
Revenue	0 FY undefined	0 FY undefined	0 FY undefined	0 FY undefined
Sources	2	0	0	0

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.

Click Now. Join a live demo

Join a demo

Looking for a leg up on competitive, customer and technology insights?

CB Insights puts confidence and clarity into your most strategic decisions.

See how. Join a demo.

Join a demo

Trusted by the world's smartest companies to:

Predict emerging trends
See competitors' playbooks
Stalk the smart money
Identify tomorrow's challengers
Spot growing industries
Kill analyst data work

Let's see how we can help you!

Halozyme Therapeutics Investors

6 Investors

Halozyme Therapeutics has 6 investors. Roche Venture Fund invested in Halozyme Therapeutics's Unattributed VC - II funding round.

First funding	Last Funding	Investor	Rounds	Board Seats	Type	Location
12/5/2006	12/5/2006	Roche Venture Fund	1 Unattributed VC - II		Corporate Venture	Switzerland
00/00/0000	00/00/0000	Ritchie Capital Management	Subscribe to see more		Hedge Fund	Illinois
00/00/0000	00/00/0000	Colt Ventures	Subscribe to see more		Venture Capital	Texas
00/00/0000	00/00/0000	Cimarron Biomedical Investors	Subscribe to see more		Private Equity	Texas
00/00/0000	00/00/0000	SuRo Capital	Subscribe to see more		Venture Capital	California

First funding	12/5/2006	00/00/0000	00/00/0000	00/00/0000	00/00/0000
Last Funding	12/5/2006	00/00/0000	00/00/0000	00/00/0000	00/00/0000
Investor	Roche Venture Fund	Ritchie Capital Management	Colt Ventures	Cimarron Biomedical Investors	SuRo Capital
Rounds	1 Unattributed VC - II	Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more
Board Seats
Type	Corporate Venture	Hedge Fund	Venture Capital	Private Equity	Venture Capital
Location	Switzerland	Illinois	Texas	Texas	California

Halozyme Therapeutics Acquisitions

1 Acquisition

Halozyme Therapeutics acquired 1 company. Their latest acquisition was Antares Pharma on May 24, 2022.

Date	Investment Stage	Companies	Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.	Total Funding	Note	Sources
5/24/2022	Other Venture Capital	Antares Pharma	$99M	$6.2M	Acq - P2P	5

Date	5/24/2022
Investment Stage	Other Venture Capital
Companies	Antares Pharma
Valuation	$99M
Total Funding	$6.2M
Note	Acq - P2P
Sources	5

Looking for a leg up on competitive, customer and technology insights?

CB Insights puts confidence and clarity into your most strategic decisions.

See how. Join a demo.

Join a demo

Trusted by the world's smartest companies to:

Predict emerging trends
See competitors' playbooks
Stalk the smart money
Identify tomorrow's challengers
Spot growing industries
Kill analyst data work

Let's see how we can help you!

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.